In addition, pre-clinical NSCLC models have demonstrated loss of SLC46A3 expression as a mechanism of acquired resistance to DM1 (emtansine payload)99, and high expression of TUBB3 and FOXO3α in NSCLC has correlated with resistance to taxane-based ADC payloads100. Here, SLC46A3 is linked to non-small cell lung carcinoma.